Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 4

Guidance for Industry

Pathologic Complete Response in Neoadjuvant Treatment of High-

Risk Early-Stage Breast

Cancer: Use as an Endpoint to Support Accelerated Approval

May 2012

Rationale for Neoadjuvant Treatment

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3 5,6,7,8,9,10,11,12,13,14,...47